Cantor Fitzgerald Reiterates “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD)

Lucid Diagnostics (NASDAQ:LUCD)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report issued on Wednesday,Benzinga reports. They presently have a $2.00 target price on the stock. Cantor Fitzgerald’s price target points to a potential upside of 25.79% from the stock’s current price.

LUCD has been the topic of a number of other reports. Needham & Company LLC boosted their target price on shares of Lucid Diagnostics from $2.50 to $3.00 and gave the stock a “buy” rating in a report on Monday. Ascendiant Capital Markets lowered their price objective on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a research report on Monday, December 9th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Lucid Diagnostics currently has a consensus rating of “Buy” and an average price target of $3.40.

Lucid Diagnostics Stock Performance

Shares of NASDAQ:LUCD opened at $1.59 on Wednesday. Lucid Diagnostics has a 52-week low of $0.63 and a 52-week high of $1.63. The company has a market capitalization of $94.35 million, a PE ratio of -1.39 and a beta of 1.34. The company has a fifty day moving average of $1.26 and a 200-day moving average of $1.00.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. LPL Financial LLC increased its holdings in Lucid Diagnostics by 29.1% in the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock worth $44,000 after purchasing an additional 12,035 shares in the last quarter. Lido Advisors LLC grew its holdings in Lucid Diagnostics by 40.0% in the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company’s stock worth $115,000 after purchasing an additional 40,000 shares during the period. Geode Capital Management LLC raised its holdings in shares of Lucid Diagnostics by 30.9% during the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company’s stock valued at $229,000 after purchasing an additional 65,964 shares during the period. Sunbelt Securities Inc. bought a new position in shares of Lucid Diagnostics during the 4th quarter worth about $67,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Lucid Diagnostics in the 4th quarter valued at about $98,000. 74.01% of the stock is owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.